SE462848B - Karbostyrilderivat, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner - Google Patents

Karbostyrilderivat, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner

Info

Publication number
SE462848B
SE462848B SE8303813A SE8303813A SE462848B SE 462848 B SE462848 B SE 462848B SE 8303813 A SE8303813 A SE 8303813A SE 8303813 A SE8303813 A SE 8303813A SE 462848 B SE462848 B SE 462848B
Authority
SE
Sweden
Prior art keywords
group
carbon
carbostyril
formula
lower alkyl
Prior art date
Application number
SE8303813A
Other languages
English (en)
Swedish (sv)
Other versions
SE8303813L (sv
SE8303813D0 (sv
Inventor
M Uchida
M Komastu
K Nakagawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP57117312A external-priority patent/JPS597169A/ja
Priority claimed from JP57117311A external-priority patent/JPS597168A/ja
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SE8303813D0 publication Critical patent/SE8303813D0/xx
Publication of SE8303813L publication Critical patent/SE8303813L/xx
Publication of SE462848B publication Critical patent/SE462848B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
SE8303813A 1982-07-05 1983-07-04 Karbostyrilderivat, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner SE462848B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57117312A JPS597169A (ja) 1982-07-05 1982-07-05 カルボスチリル誘導体
JP57117311A JPS597168A (ja) 1982-07-05 1982-07-05 カルボスチリル誘導体

Publications (3)

Publication Number Publication Date
SE8303813D0 SE8303813D0 (sv) 1983-07-04
SE8303813L SE8303813L (sv) 1984-01-06
SE462848B true SE462848B (sv) 1990-09-10

Family

ID=26455454

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8303813A SE462848B (sv) 1982-07-05 1983-07-04 Karbostyrilderivat, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner

Country Status (17)

Country Link
US (2) US4578381A (fr)
AT (1) AT385506B (fr)
AU (1) AU552717B2 (fr)
CA (1) CA1247624A (fr)
CH (1) CH654578A5 (fr)
DE (1) DE3324034A1 (fr)
DK (1) DK168288B1 (fr)
ES (4) ES8500906A1 (fr)
FI (1) FI80022C (fr)
FR (1) FR2530626B1 (fr)
GB (1) GB2123825B (fr)
IT (1) IT1203676B (fr)
NL (1) NL194165C (fr)
NO (1) NO164835C (fr)
PH (1) PH21650A (fr)
PT (1) PT76980B (fr)
SE (1) SE462848B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677112A (en) * 1984-02-02 1987-06-30 Warner-Lambert Company 1,2,3,4-tetrahydro-2-oxo-8-quinolineacetic and -propanoic acids and derivatives as cognition activators
US4582909A (en) * 1984-02-02 1986-04-15 Warner-Lambert Company Benzobicyclic lactam acids and derivatives as cognition activators
KR920701162A (ko) * 1990-03-28 1992-08-11 오츠카 아끼히코 퀴놀린 유도체, 당해 유도체를 함유하는 항궤양제 및 당해 유도체의 제조방법
US5212317A (en) * 1990-12-20 1993-05-18 North Carolina State University Methods and intermediates for the assymmetric synthesis of camptothecin and camptothecin analogs
US5200524A (en) * 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5315007A (en) * 1990-12-20 1994-05-24 North Carolina State University Process for making DE ring intermediates for the synthesis of camptothecin and camptothecin analogs
US5162532A (en) * 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5258516A (en) * 1990-12-20 1993-11-02 Nc State University Optically pure D,E ring intermediates useful for the synthesis of camptothecin and camptothecin analogs
US5254690A (en) * 1990-12-20 1993-10-19 North Carolina State University Alkoxymethylpyridine d-ring intermediates useful for the synthesis of camptpthecin and camptothecin analogs
US5264579A (en) * 1990-12-20 1993-11-23 North Carolina State University D ring intermediates for the synthesis of camptothecin and camptothecin analogs
DK0543018T3 (da) * 1991-06-07 1996-02-05 Otsuka Pharma Co Ltd Antidiabetikum
TW227558B (fr) * 1992-05-14 1994-08-01 Otsuka Pharma Co Ltd
US5459269A (en) * 1992-06-18 1995-10-17 North Carolina State University 14-halo-camptothecins
US5428166A (en) * 1992-06-18 1995-06-27 North Carolina State University Method of making asymmetric de ring intermediates for the synthesis of camptothecin and camptothecin analogs
JP2872546B2 (ja) * 1992-11-26 1999-03-17 大塚製薬株式会社 腸粘膜障害保護剤
IS4164A (is) * 1993-06-11 1994-12-12 Ab Astra Efnasambönd sem hindra flæði magasýru
US5556863A (en) * 1993-06-11 1996-09-17 Astra Aktiebolag Compound for gastric acid secretion inhibition
ATE184793T1 (de) * 1993-10-21 1999-10-15 Otsuka Pharma Co Ltd Die verwendung von carbostyrilderivaten zur herstellung eines arzneimittels zur hemmung der produktion von interleukin-8
WO1995012579A1 (fr) * 1993-11-05 1995-05-11 Otsuka Pharmaceutical Company, Limited Sel de bismuth de derives de carbostyrile destines au traitement des ulceres gastro-duodenaux
US5496952A (en) * 1995-02-07 1996-03-05 North Carolina State University Method of making asymmetric DE ring intermediates for the synthesis of camptothecin and camptothecin analogs
ATE275132T1 (de) * 1995-06-27 2004-09-15 Takeda Chemical Industries Ltd 4-acylamino(halogen)alkyl-chinolin derivate, deren herstellung und deren verwendung als melatonin-agonisten
AR004214A1 (es) * 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
NZ325939A (en) * 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
AU712019B2 (en) * 1996-05-20 1999-10-28 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
KR100669823B1 (ko) * 2001-02-20 2007-01-17 경동제약 주식회사 2-(4-클로로벤조일아미노)-3-[2(1ｈ)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체
EP1648563B1 (fr) * 2003-07-30 2007-09-19 Otsuka Pharmaceutical Co., Ltd. Derives carbostyrile pour accelerer la salivation
TWI340650B (en) * 2004-01-21 2011-04-21 Otsuka Pharma Co Ltd Amine saly of carbostyril derivative
JP3911008B2 (ja) * 2004-12-01 2007-05-09 大塚製薬株式会社 レバミピドの改良製造法
JP3892894B2 (ja) * 2005-04-28 2007-03-14 大塚製薬株式会社 カルボスチリル化合物の製造法
CN101870674B (zh) * 2009-04-21 2012-04-18 陕西大生化学科技有限公司 改进的瑞巴派特中间体的制备方法
US9248196B2 (en) * 2011-02-25 2016-02-02 Nuformix Limited Rebamipide complexes and cocrystals
CN102153512B (zh) * 2011-03-07 2013-03-27 江西同和药业有限责任公司 瑞巴派特中间体的制备方法
SA113340675B1 (ar) * 2012-06-26 2015-08-16 استيش. كو.، ليمتد أدوية ريباميبايد تحضيرية جديدة، طريقة تحضيرها واستخدامها
CN108341775B (zh) * 2017-01-25 2021-03-16 重庆常捷医药有限公司 一种瑞巴派特中间体的合成方法
KR102190019B1 (ko) 2018-10-23 2020-12-15 삼진제약주식회사 쇼그렌 증후군 예방 또는 치료용 조성물
CN111057001A (zh) * 2019-12-23 2020-04-24 巨化集团公司制药厂 一种喹诺酮丙二酸酯化合物的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632628A (en) * 1968-04-15 1972-01-04 Colgate Palmolive Co Sulfonamidoalkyl amino acids
US4022776A (en) * 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
FI59246C (fi) * 1974-06-24 1981-07-10 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av benscykloamidderivat anvaendbara vid trombos- och emboliterapin
US4313947A (en) * 1974-06-24 1982-02-02 Otsuka Pharmaceutical Co., Ltd. Platelet aggregation inhibiting 2-oxyindoles, their compositions and method of use
US4065572A (en) * 1976-02-13 1977-12-27 Merck & Co., Inc. Amino acids and esters thereof useful as antihypertensive agents
US4156734A (en) * 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
JPS5387368A (en) * 1977-01-12 1978-08-01 Otsuka Pharmaceut Co Ltd Carbostyril derivative
NZ187452A (en) * 1977-06-10 1980-05-27 Otsuka Pharma Co Ltd N- substituted-aminocarbonylpropoxy-carbostyrils and their preparation
JPS5535018A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Alkaneamide derivative
JPS5583749A (en) * 1978-12-19 1980-06-24 Yoshitomi Pharmaceut Ind Ltd Quinolone derivative
JPS5585520A (en) * 1978-12-22 1980-06-27 Otsuka Pharmaceut Co Ltd Remedy for peptic ulcer
DE2927534A1 (de) * 1979-07-07 1981-01-08 Bayer Ag Optisch reine heterocyclische aminosaeuren, verfahren zu ihrer herstellung und ihre verwendung
JPS56122356A (en) * 1980-02-29 1981-09-25 Otsuka Pharmaceut Co Ltd Carbostyril derivative
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS574974A (en) * 1980-06-11 1982-01-11 Otsuka Pharmaceut Co Ltd Carbostyril derivative
FI77852C (fi) * 1981-02-17 1989-05-10 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av nya, saosom hjaertmediciner anvaendbara substituerade amid- och (maettad heterocykel)karbonylkarbostyrilderivat.
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives

Also Published As

Publication number Publication date
ES523838A0 (es) 1984-11-01
PT76980B (en) 1986-01-09
FR2530626A1 (fr) 1984-01-27
ES8504724A1 (es) 1985-05-01
ES530716A0 (es) 1985-05-01
ES8505348A1 (es) 1985-05-16
DE3324034C2 (fr) 1993-07-01
AU552717B2 (en) 1986-06-19
CH654578A5 (de) 1986-02-28
NL194165C (nl) 2001-08-03
NO164835C (no) 1990-11-21
ES530714A0 (es) 1985-05-16
DK168288B1 (da) 1994-03-07
GB8318174D0 (en) 1983-08-03
NO832431L (no) 1984-01-06
PH21650A (en) 1988-01-13
US4578381A (en) 1986-03-25
GB2123825B (en) 1985-09-18
FI832425A0 (fi) 1983-07-01
ES8500906A1 (es) 1984-11-01
NL194165B (nl) 2001-04-02
FI832425L (fi) 1984-01-06
CA1247624A (fr) 1988-12-28
SE8303813L (sv) 1984-01-06
NL8302390A (nl) 1984-02-01
FR2530626B1 (fr) 1986-12-05
IT8367731A0 (it) 1983-07-05
ES8505347A1 (es) 1985-05-16
DE3324034A1 (de) 1984-01-05
AT385506B (de) 1988-04-11
GB2123825A (en) 1984-02-08
AU1653683A (en) 1984-01-12
ATA245183A (de) 1987-09-15
PT76980A (en) 1983-08-01
FI80022C (fi) 1990-04-10
NO164835B (no) 1990-08-13
USRE34722E (en) 1994-09-06
FI80022B (fi) 1989-12-29
ES530715A0 (es) 1985-05-16
DK307883D0 (da) 1983-07-04
DK307883A (da) 1984-01-06
IT1203676B (it) 1989-02-15
SE8303813D0 (sv) 1983-07-04

Similar Documents

Publication Publication Date Title
SE462848B (sv) Karbostyrilderivat, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner
JP3165867B2 (ja) カルボスチリル誘導体及びバソプレシン拮抗剤
SE466655B (sv) Karboxylsyrafoereningar samt foerfarande foer framstaellning daerav
DE3826846A1 (de) Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
BG107460A (bg) Производни на бензимидазола, тяхното получаване иприложението им в терапията
EP2665706B1 (fr) Nouveaux 4-amino-n-hydroxy-benzamides en tant qu'inhibiteurs de hdac pour le traitement du cancer
JPH07500591A (ja) 三環性キノキサリンジオン化合物
DE60012883T2 (de) 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepin-3-hydroxamsäure als matrix metalloproteinaseinhibitoren
CA2908963A1 (fr) Derives de perhydroquinoxaline utiles en tant qu'analgesiques
SE449862B (sv) Substituerade, heterocykliska bensamider, sett att framstella dessa och en faramakologisk komposition
JP2002501056A (ja) マトリクス金属プロテイナーゼ阻害薬としての２，３，４，５−テトラヒドロ−１ｈ−［１，４］−ベンゾジアゼピン−３−ヒドロキサム酸
JP2614756B2 (ja) イミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
WO2006027366A1 (fr) Derives de 1-deaza purine 2-substitues possedant une activite modulant le recepteur de l'adenosine
JPH03127732A (ja) バソプレシン拮抗剤
EP1758872A1 (fr) Procede pour la preparation d'anastrozole
DE10155018A1 (de) Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel
CZ2002759A3 (cs) Meziprodukty pro přípravu derivátů chinolonkarboxylové kyseliny
EP0646116B1 (fr) Procede et intermediaires pour agents anxiolitiqes bis-aza-bicycliques
EP0347851B1 (fr) Acides quinolonecarboxyliques
US5763453A (en) Condensed indan derivatives and salts thereof
DE19754490A1 (de) Durch einen Aminocarbonylrest substituierte Bicyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
WO1999003858A1 (fr) Derives purine et leur application medicinale
RU2049776C1 (ru) Производное хинона или его фармакологически приемлемые соли
US20220041593A1 (en) Synthesis for 3-bromo-5-(2-ethylimidazo[1, 2-alpha]pyridine- 3-carbonyl)-2-hydroxybenzonitrile
EP1094066A2 (fr) Dérivés hétérocycliques condensés de l'acide glutamique utilisés comme agents antiprolifératifs

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8303813-3

Format of ref document f/p: F

NUG Patent has lapsed